Hyperfine (NASDAQ:HYPR) Announces Earnings Results

Hyperfine (NASDAQ:HYPR) announced its quarterly earnings results on Tuesday. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09), FiscalAI reports. The company had revenue of $3.90 million for the quarter, compared to the consensus estimate of $3.54 million. Hyperfine had a negative net margin of 262.29% and a negative return on equity of 95.09%.

Here are the key takeaways from Hyperfine’s conference call:

• Hyperfine posted Q1 2026 revenue of $3.9 million, up 83% year over year, making it the company’s second-highest quarter ever and supported by sales across all three business verticals.
• Gross margin expanded to 50.7%, the third straight quarter above 50%, while net cash burn improved to $8.8 million from $10.1 million a year ago, showing better operating leverage and spending discipline.
• Management reiterated full-year 2026 guidance for $20 million-$22 million in revenue, 50%-55% gross margin, and $26 million-$28 million in cash burn, while saying the business should strengthen through the year.
• The company highlighted several commercial and regulatory milestones, including CE and UKCA marks for the next-generation system and Optive AI software, more than 50% enrollment in the Contrast PMR study, and strong reception to its advanced DWI software.
• Hyperfine sees growth coming from hospitals/IDNs, neurology offices, and international markets, with an expanding pipeline of multi-site IDN deals and plans to launch in Europe in the third quarter; the company also discussed future use in OR and angio-suite settings.

Hyperfine Trading Down 1.1%

Shares of HYPR stock traded down $0.02 during trading hours on Tuesday, reaching $1.73. 820,006 shares of the stock were exchanged, compared to its average volume of 537,376. Hyperfine has a 12-month low of $0.53 and a 12-month high of $2.22. The company’s 50-day moving average price is $1.25 and its 200-day moving average price is $1.15. The firm has a market capitalization of $169.47 million, a price-to-earnings ratio of -3.93 and a beta of 1.42.

Insider Activity

In other Hyperfine news, CFO Brett Hale sold 24,188 shares of the business’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $1.21, for a total value of $29,267.48. Following the completion of the sale, the chief financial officer directly owned 275,812 shares of the company’s stock, valued at $333,732.52. The trade was a 8.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Thomas Teisseyre sold 24,188 shares of the business’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $1.21, for a total transaction of $29,267.48. Following the completion of the sale, the chief operating officer directly owned 354,648 shares of the company’s stock, valued at approximately $429,124.08. This trade represents a 6.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 26.33% of the stock is owned by insiders.

Institutional Investors Weigh In On Hyperfine

Several large investors have recently added to or reduced their stakes in HYPR. Vanguard Group Inc. boosted its position in Hyperfine by 5.7% in the 3rd quarter. Vanguard Group Inc. now owns 3,511,972 shares of the company’s stock valued at $5,092,000 after buying an additional 190,136 shares during the period. Geode Capital Management LLC boosted its position in Hyperfine by 21.4% in the 4th quarter. Geode Capital Management LLC now owns 815,986 shares of the company’s stock valued at $799,000 after buying an additional 143,975 shares during the period. Cerity Partners LLC purchased a new stake in Hyperfine in the 4th quarter valued at about $59,000. Renaissance Technologies LLC boosted its position in Hyperfine by 674.4% in the 4th quarter. Renaissance Technologies LLC now owns 364,743 shares of the company’s stock valued at $357,000 after buying an additional 317,645 shares during the period. Finally, State Street Corp boosted its position in Hyperfine by 6.1% in the 4th quarter. State Street Corp now owns 265,195 shares of the company’s stock valued at $260,000 after buying an additional 15,200 shares during the period. 15.03% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HYPR has been the subject of a number of recent research reports. BTIG Research initiated coverage on shares of Hyperfine in a research note on Wednesday, April 29th. They issued a “buy” rating and a $2.00 price objective for the company. Lake Street Capital lifted their price objective on shares of Hyperfine from $2.00 to $2.50 and gave the stock a “buy” rating in a research note on Thursday, March 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Hyperfine in a research note on Tuesday, April 21st. Finally, Zacks Research raised shares of Hyperfine to a “hold” rating in a research note on Thursday, March 19th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Hyperfine currently has an average rating of “Hold” and a consensus target price of $1.59.

Hyperfine Company Profile

Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company’s flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.

The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient’s bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients.